Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06296550 · ClinicalTrials.gov registry record · NA
Enhancing Digitally Delivered Diabetes Education With Real-Time CGM
A NA study of Diabetes Type 2, sponsored by Scripps Whittier Diabetes Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT06296550: Recruiting NA study of Diabetes Type 2, sponsored by Scripps Whittier Diabetes Institute.
NCT06296550 is a NA study of Diabetes Type 2 that is actively recruiting participants, run by Scripps Whittier Diabetes Institute. The registered enrollment target is 140 participants, below the 662-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06296550, a NA study of Diabetes Type 2, is actively recruiting participants, sponsored by Scripps Whittier Diabetes Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
Primary Outcome
Measures participants A1c using lab results provided from healthcare provider.
Conditions Studied
Interventions
- OTHER Dulce Digital Text Messaging Intervention
- OTHER CGM Device
Study Locations (1)
California
- Scripps Whittier Diabetes Institute - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-04-03 |
| Est. Completion | 2027-04-30 |
| Phase | NA |
What NCT06296550 shows while recruiting
NCT06296550 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 662-participant average among 24 other Diabetes Type 2 trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Diabetes Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Dulce Digital Text Messaging Intervention is the first listed.
NCT06296550 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06296550 about?
NCT06296550 is a clinical study titled "Enhancing Digitally Delivered Diabetes Education With Real-Time CGM". The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.
What is the current status of trial NCT06296550?
This trial is currently recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2025-04-03. Estimated completion is 2027-04-30.
What conditions does trial NCT06296550 study?
This clinical trial studies the following conditions: Diabetes Type 2.
What interventions are being tested in trial NCT06296550?
The interventions under investigation include: Dulce Digital Text Messaging Intervention (OTHER), CGM Device (OTHER).
Who is sponsoring clinical trial NCT06296550?
This trial is sponsored by Scripps Whittier Diabetes Institute, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06296550 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06296550's enrollment target sits among peer trials
140 14th of 24 higher than 11 of 24 other Diabetes Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity
RECRUITING · NA
-
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
RECRUITING · NA
-
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
RECRUITING · NA
-
FELLAShip to Better Health
RECRUITING · NA
-
Healthy Living Anson Study
RECRUITING · NA
-
Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI